Business Combination

Westin Acquisition Corp (WSTN) priced its $50 million IPO of 5,000,000 units at $10.00 per unit, each containing one Class A share and a right to 1/6 of a share. Trading on Nasdaq under WSTNU is expected to begin November 4, 2025, with closing anticipated November 5, 2025. Underwriters have a 45-day option to purchase up to 750,000 additional units. A.G.P./Alliance Global Partners is the sole book-running manager.

Harvard Ave Acquisition Corporation (HAVAU) closed its $145 million IPO, offering 14,500,000 units at $10.00 each. Units, trading on Nasdaq under HAVAU since October 23, 2025, consist of Class A ordinary shares and rights, expected to list as HAVA and HAVAR, respectively. The Cayman Islands-based SPAC, managed by D. Boral Capital, will pursue a business combination. Investors should note the risks inherent in SPACs, including target selection and regulatory scrutiny.

GSR IV Acquisition Corp. (GSRF) has closed its $230 million IPO, including the full exercise of the over-allotment option. The offering consisted of 23 million units at $10.00 each. Each unit includes one Class A ordinary share and one-seventh of a right, convertible into shares upon a business combination. Units trade on Nasdaq under “GSRFU,” with shares and rights to follow under “GSRF” and “GSRFR.” Polaris Advisory Partners and The Benchmark Company were joint bookrunners; the latter acting as qualified independent underwriter. GSRF is a blank check company seeking a merger target.

Relief Therapeutics will merge with NeuroX, the successor to MindMaze, in a deal valuing Relief at CHF 100M and NeuroX at CHF 1B. Relief shareholders will own approximately 9% of the combined entity, focused on AI-based digital neurotherapeutics. NeuroX, which acquired MindMaze’s assets, brings a clinically validated platform with over $350M invested. The transaction is expected to close in Q4 2025, pending approvals and customary conditions. The merger aims to create a publicly listed, AI-driven health tech enterprise.